Abivax shareholders vote on 10% fully diluted warrant issue without subscription rights

• Abivax shareholders will vote May 11, 2026 on Resolution 29 to delegate authority to board to issue ordinary share subscription warrants (BSA) with pre-emptive rights waived.
• Mandate would allow one or more warrant issues targeting strategic partners or company and subsidiary executives or employees.
• Maximum warrants issuable would be capped at 10% of fully diluted share capital as of meeting date, within overall ceiling set in Resolution 31.
• Statutory auditors raised no objections to pricing methodology described for any shares issued on warrant exercise.
• Proxy vote: For.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.